WHWK - NASDAQ

Whitehawk Therapeutics Inc

WHWK·NASDAQ

$4.18

+6.1%

HealthcareBiotechnology

Whitehawk Therapeutics Inc operates as a clinical-stage biopharmaceutical company. The Company develops precision therapies for genetically-defined cancers.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$206.71M

EPS-0.3300

P/E Ratio-7.27

Earnings Date08/06/2026

150.83M

Assets

114%

3Y-18.0%

5Y+701.0%

10Y+805.0%

14.52M

Total Liabilities

-19%

3Y-44.0%

5Y-54.0%

10Y-44.0%

136.31M

Total Equity

160%

3Y-14.0%

5Y-1196.0%

10Y-1599.0%

Whitehawk Therapeutics Inc Funding & Solvency Profile

WHWK · NASDAQ

Current Assets

Cash & Cash Equivalents37.57M

Net Receivables0.00

Inventory0.00

Other Current Assets3.32M

Total Current Assets149 M

Non-Current Assets

Property, Plant & Equipment3.00K

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets1.81M

Total Non-Current Assets2 M

Total Assets

150.83M

Financial Health Analysis

Current Ratio

10.26x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.11x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

134 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

99% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Whitehawk Therapeutics Inc Balance Sheet

WHWK • NASDAQ

Whitehawk Therapeutics Inc Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	37.6M	28.7M	62.9M	39M	149M	4.5M	16M
Short-Term Investments	108.1M	18.6M	46M	133.5M	0.0	0.0	0.0
Cash & Short-Term Investments	145.7M	47.2M	108.8M	172.6M	149M	4.5M	16M
Net Receivables	0.0	5.9M	5.5M	1.9M	0.0	14.1M	284.9K
Accounts Receivables	0.0	5.9M	5.5M	1.9M	0.0	14.1M	284.9K
Inventory	0.0	5.3M	6.4M	1.9M	0.0	0.0	0.0
Prepaids	0.0	2.8M	0.0	3.7M	2.3M	81K	58.9K
Other Current Assets	3.3M	0.0	3.8M	0.0	0.0	0.0	0.0
Total Current Assets	149M	61.3M	124.6M	180M	151.3M	18.7M	16.3M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	3K	7.6M	6M	2M	614K	140K	316K
Intangible Assets	0.0	0.0	0.0	0.0	3.8M	0.0	0.0
Goodwill & Intangible Assets	0.0	0.0	0.0	0.0	3.8M	0.0	0.0
Other Non-Current Assets	1.8M	1.4M	1.9M	2.2M	2.2M	0.0	37K
Total Non-Current Assets	1.8M	9M	7.8M	4.2M	6.6M	140K	352.9K
Total Assets	150.8M	70.3M	132.4M	184.2M	157.9M	18.8M	16.7M
LIABILITIES
CURRENT LIABILITIES
Total Payables	917K	2.2M	11.7M	3.5M	6.4M	2.4M	3.2M
Accounts Payable	917K	2.2M	5.9M	3.5M	6.4M	2.4M	3.2M
Other Payables	0.0	0.0	5.8M	0.0	0.0	0.0	0.0
Accrued Expenses	0.0	14.6M	11.2M	13.4M	8.7M	6.9M	2.2M
Short Term Debt	0.0	0.0	0.0	0.0	0.0	9M	8.2M
Capital Lease Obligations (Current)	0.0	268K	434K	394K	131K	125K	188.3K
Other Current Liabilities	13.6M	64K	3.1M	1.6M	0.0	11.6M	11.9M
Total Current Liabilities	14.5M	17.1M	26.4M	18.8M	15.3M	30.1M	25.6M
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	1.1M	0.0
Other Non-Current Liabilities	0.0	202K	0.0	5.8M	5.8M	97K	0.0
Total Non-Current Liabilities	0.0	767K	833K	7M	6.2M	1.2M	133.5K
Capital Lease Obligations	0.0	833K	1.3M	1.7M	605K	125K	321.7K
Total Liabilities	14.5M	17.8M	27.2M	25.9M	21.5M	31.3M	25.8M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	1K	794.0
Common Stock	4K	2K	2K	2K	2K	1K	802.0
Additional Paid-In Capital	489.4M	385.1M	374.1M	361.7M	279.1M	20.2M	20M
Retained Earnings	-353.3M	-332.7M	-269M	-203.2M	-142.7M	-32.6M	-29.1M
Accumulated Other Comprehensive Income/Loss	120K	16K	27K	-115K	0.0	0.0	0.0
Total Stockholders' Equity	136.3M	52.5M	105.2M	158.4M	136.4M	-12.4M	-9.1M
Total Equity	136.3M	52.5M	105.2M	158.4M	136.4M	-12.4M	-9.1M
SUMMARY
Total Liabilities & Equity	150.8M	70.3M	132.4M	184.2M	157.9M	18.8M	16.7M
Total Investments	108.1M	18.6M	46M	133.5M	0.0	0.0	0.0
Total Debt	0.0	833K	1.3M	1.7M	605K	10.3M	8.5M
Net Debt	-37.6M	-27.8M	-61.6M	-37.4M	-148.4M	5.8M	-7.5M
Shares Outstanding	47,128,362	47,128,362	47,128,362	47,128,362	47,128,362	47,128,362	47,128,362

SEC Filings

WHWK - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
S-3 S-3 N/A	May 29, 2026	May 29, 2026		View Filing
8-K 8-K 2026 N/A	May 21, 2026	May 21, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 13, 2026	May 12, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 28, 2026	April 28, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 12, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 12, 2026	March 12, 2026	2026	View Filing
8-K 8-K 2025 N/A	November 06, 2025	November 06, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 06, 2025	September 30, 2025	2025	View Filing

Showing 1 to 10 of 204 filings

Related Guides

Blog Categories

Continue your WHWK research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.